|
1
|
Li Y, Song S, Pizzi MP, Han G, Scott AW, Jin J, Xu Y, Wang Y, Huo L, Ma L, Vellano C, Luo X, MacLeod R, Wang L, Wang Z, Ajani JA. LncRNA PVT1 Is a Poor Prognosticator and Can Be Targeted by PVT1 Antisense Oligos in Gastric Adenocarcinoma. Cancers (Basel) 2020; 12:cancers12102995. [PMID: 33076512 PMCID: PMC7602573 DOI: 10.3390/cancers12102995] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2020] [Revised: 10/09/2020] [Accepted: 10/13/2020] [Indexed: 12/14/2022] Open
Abstract
Gastric adenocarcinoma (GAC) is inherently resistant or becomes resistant to therapy, leading to a poor prognosis. Mounting evidence suggests that lncRNAs can be used as predictive markers and therapeutic targets in the right context. In this study, we determined the role of lncRNA-PVT1 in GAC along with the value of inhibition of PVT1 using antisense oligos (ASOs). RNA scope in situ hybridization was used to analyze PVT1 expression in tumor tissue microarrays (TMAs) of GAC and paired normal tissues from 792 patients. Functional experiments, including colony formation and invasion assays, were performed to evaluate the effects of PVT1 ASO inhibition of PVT1 in vitro; patient-derived xenograft models were used to evaluate the anti-tumor effects of PVT1 ASOs in vivo. LncRNA-PVT1 was upregulated in GACs compared to the matched adjacent normal tissues in the TMA. LncRNA PVT1 expression was positively correlated with larger tumor size, deeper wall invasion, lymph node metastases, and short survival duration. Inhibition of PVT1 using PVT1 ASOs significantly suppressed tumor cell growth and invasion in vitro and in vivo. PVT1 expression was highly associated with poor prognosis in GAC patients and targeting PVT1 using PVT1 ASOs was effective at curtailing tumor cell growth in vitro and in vivo. Thus, PVT1 is a poor prognosticator as well as therapeutic target. Targeting PVT1 using PVT1 ASOs provides a novel therapeutic strategy for GAC.
Collapse
Affiliation(s)
- Yuan Li
- Department of Gastrointestinal Medical Oncology, Unit 0426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; (Y.L.); (S.S.); (M.P.P.); (A.W.S.); (J.J.); (Y.X.); (Y.W.); (L.H.); (L.M.)
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang 110001, China
| | - Shumei Song
- Department of Gastrointestinal Medical Oncology, Unit 0426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; (Y.L.); (S.S.); (M.P.P.); (A.W.S.); (J.J.); (Y.X.); (Y.W.); (L.H.); (L.M.)
| | - Melissa Pool Pizzi
- Department of Gastrointestinal Medical Oncology, Unit 0426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; (Y.L.); (S.S.); (M.P.P.); (A.W.S.); (J.J.); (Y.X.); (Y.W.); (L.H.); (L.M.)
| | - Guangchun Han
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (G.H.); (L.W.)
| | - Ailing W. Scott
- Department of Gastrointestinal Medical Oncology, Unit 0426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; (Y.L.); (S.S.); (M.P.P.); (A.W.S.); (J.J.); (Y.X.); (Y.W.); (L.H.); (L.M.)
| | - Jiankang Jin
- Department of Gastrointestinal Medical Oncology, Unit 0426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; (Y.L.); (S.S.); (M.P.P.); (A.W.S.); (J.J.); (Y.X.); (Y.W.); (L.H.); (L.M.)
| | - Yan Xu
- Department of Gastrointestinal Medical Oncology, Unit 0426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; (Y.L.); (S.S.); (M.P.P.); (A.W.S.); (J.J.); (Y.X.); (Y.W.); (L.H.); (L.M.)
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang 110001, China
| | - Ying Wang
- Department of Gastrointestinal Medical Oncology, Unit 0426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; (Y.L.); (S.S.); (M.P.P.); (A.W.S.); (J.J.); (Y.X.); (Y.W.); (L.H.); (L.M.)
| | - Longfei Huo
- Department of Gastrointestinal Medical Oncology, Unit 0426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; (Y.L.); (S.S.); (M.P.P.); (A.W.S.); (J.J.); (Y.X.); (Y.W.); (L.H.); (L.M.)
| | - Lang Ma
- Department of Gastrointestinal Medical Oncology, Unit 0426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; (Y.L.); (S.S.); (M.P.P.); (A.W.S.); (J.J.); (Y.X.); (Y.W.); (L.H.); (L.M.)
| | - Christopher Vellano
- Center for Co-Clinical Trials, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA;
| | - Xiaolin Luo
- Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010, USA; (X.L.); (R.M.)
| | - Robert MacLeod
- Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010, USA; (X.L.); (R.M.)
| | - Linghua Wang
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (G.H.); (L.W.)
| | - Zhenning Wang
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang 110001, China
- Correspondence: (Z.W.); (J.A.A.); Tel.: +1-713-792-3685 (Z.W.)
| | - Jaffer A. Ajani
- Department of Gastrointestinal Medical Oncology, Unit 0426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; (Y.L.); (S.S.); (M.P.P.); (A.W.S.); (J.J.); (Y.X.); (Y.W.); (L.H.); (L.M.)
- Correspondence: (Z.W.); (J.A.A.); Tel.: +1-713-792-3685 (Z.W.)
| |
Collapse
|
|
2
|
Abstract
Gastric cancer affects annually more than 800,000 individuals worldwide and remains a challenge for clinicians and oncologists. Most patients with gastric cancer are diagnosed in advanced stages, when a curative resection is impossible, which leads to an overall poor prognosis. Finding new diagnostic and treatment procedures is of paramount importance to improve patient prognosis, which will be improved most dramatically by techniques that allow the detection of gastric cancer in its early stages. So far the value of conventional tumour markers such as Ca72-4 or carcinoembryonic antigen is limited, and even markers developed from molecular biological studies on the carcinogenesis of gastric cancer, such as E-cadherin and others, have not proved to be of adequate sensitivity and specificity to allow the early detection of gastric cancer. With the development of innovative diagnostic tools, such as proteome analysis, new biomarkers may be identified that may allow early diagnosis and thus screening for gastric cancer, particularly in at-risk patient populations. Recent studies have indicated that these biomarkers may be derived from the tumour itself or reflect a specific metabolic or immunological response to cancer that can be used to find gastric cancer patients at an early and putatively curative stage of the disease.
Collapse
|